Alembic Pharmaceuticals Q4 PAT Surges 29% YoY

Alembic Pharmaceuticals reported Q4 FY26 revenue of ₹18.48 billion, a 4% YoY growth, with US formulations driving an 11% increase.
Reported PAT surged 29% YoY to ₹2.03 billion, while pre-R&D EBITDA grew 8% to ₹4.55 billion with a 25% margin.
R&D expenditure increased significantly by 39% YoY, constituting 11% of revenue, driven by peptide development and higher filings.
The India branded business grew 4% with ₹5.68 billion revenue, maintaining a 1.2% market share and ranking 21st in the IPM.